Celltrion to Showcase Cutting-Edge Research on IBD Treatment at 2026 Digestive Disease Week in Chicago
Introducing Celltrion's Contributions to IBD Management at the 2026 DDW
Celltrion, Inc., a significant player in the biopharmaceutical industry, has made a monumental announcement regarding their participation in the 2026 Digestive Disease Week (DDW), scheduled from May 2-5 in Chicago, Illinois. The company will present seven abstracts that underline their commitment to advancing treatment for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.
The Importance of 2026 DDW
The Digestive Disease Week (DDW) is one of the largest platforms for healthcare professionals to converge, sharing vital research findings and clinical advancements in gastroenterology and hepatology. Sponsored by renowned associations like the American Gastroenterological Association (AGA) and the American Society for Gastrointestinal Endoscopy (ASGE), this annual meeting is pivotal for experts like Celltrion to showcase their findings.
Highlights of Celltrion's Presentations
Among the seven abstracts, several key presentations will capture attention:
1. Long-term Effects of Therapy - Preliminary findings from the PROFILE study highlight that early intervention using
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.